TY - JOUR
T1 - Cytokines, brain proteins, and growth factors in acute stroke patients
T2 - A pilot study
AU - Zafar, Atif
AU - Farooqui, Mudassir
AU - Ikram, Asad
AU - Suriya, Sajid
AU - Kempuraj, Duraisamy
AU - Khan, Mohammad
AU - Tasneem, Nudrat
AU - Qaryouti, Dania
AU - Quadri, Syed
AU - Adams, Harold P.
AU - Ortega-Gutierrez, Santiago
AU - Leira, Enrique
AU - Zaheer, Asgar
N1 - Publisher Copyright:
© 2021 Published by Scientific Scholar on behalf of Surgical Neurology International
PY - 2021
Y1 - 2021
N2 - Background: Immunomodulation and cell signaling involve several cytokines, proteins, and other mediators released in response to the trauma, inflammation, or other insults to the central nervous system. This pilot study is part of the registry designed to evaluate the temporal trends among these molecules after an acute ischemic stroke (AIS) in patients. Methods: Twelve AIS patients were enrolled within 24 hours of the symptoms onset. Two sets of plasma samples were collected: First at admission and second at 24 hours after admission. Cytokines/chemokines and other inflammatory molecules were measured using multiplex assay kit. Results: An increased trend in IL-6 (22 vs. 34 pg/ml), IL-8/CXCL8 (87 vs. 98 pg/ml), MMP-9 (16225 vs. 18450 pg/ml), and GMF-β (999 vs. 3739 pg/ml) levels was observed overtime after an AIS. Patients ≤60 years had lower levels of plasma MCP-1/CCL2 (50–647 vs. 150–1159 pg/ml), IL-6 (9–25 vs. 20–68 pg/ml), and IL-8 (30–143 vs. 72–630 pg/ml), when compared with patients >60 years old. Conclusion: Cytokines/chemokines and other inflammatory mediators play an important role in the pathogenesis of stroke in addition to mediating poststroke inflammation. Further research is needed to evaluate and characterize the cumulative trends of these mediators for the clinical prognosis or as surrogate biomarkers.
AB - Background: Immunomodulation and cell signaling involve several cytokines, proteins, and other mediators released in response to the trauma, inflammation, or other insults to the central nervous system. This pilot study is part of the registry designed to evaluate the temporal trends among these molecules after an acute ischemic stroke (AIS) in patients. Methods: Twelve AIS patients were enrolled within 24 hours of the symptoms onset. Two sets of plasma samples were collected: First at admission and second at 24 hours after admission. Cytokines/chemokines and other inflammatory molecules were measured using multiplex assay kit. Results: An increased trend in IL-6 (22 vs. 34 pg/ml), IL-8/CXCL8 (87 vs. 98 pg/ml), MMP-9 (16225 vs. 18450 pg/ml), and GMF-β (999 vs. 3739 pg/ml) levels was observed overtime after an AIS. Patients ≤60 years had lower levels of plasma MCP-1/CCL2 (50–647 vs. 150–1159 pg/ml), IL-6 (9–25 vs. 20–68 pg/ml), and IL-8 (30–143 vs. 72–630 pg/ml), when compared with patients >60 years old. Conclusion: Cytokines/chemokines and other inflammatory mediators play an important role in the pathogenesis of stroke in addition to mediating poststroke inflammation. Further research is needed to evaluate and characterize the cumulative trends of these mediators for the clinical prognosis or as surrogate biomarkers.
KW - Acute ischemic brain injury
KW - Cytokine
KW - Interleukin
KW - Poststroke inflammation
KW - Stroke
UR - https://www.scopus.com/pages/publications/85111540475
UR - https://www.scopus.com/pages/publications/85111540475#tab=citedBy
U2 - 10.25259/SNI_569_2021
DO - 10.25259/SNI_569_2021
M3 - Article
AN - SCOPUS:85111540475
SN - 2152-7806
VL - 12
JO - Surgical Neurology International
JF - Surgical Neurology International
M1 - 366
ER -